

lasted for only a few hours. Histopathological examination of PGA-treated animals showed that a large number of these animals had acute renal tubular necrosis (fig.). In only one DBA/2 mouse, there was shrinkage of a few Purkinje cells in the cerebellum.

Discussion. PGA, as a water-soluble vitamin supplement, is expected to have a very high LD₅₀ value, unlike drugs. It was surprising, therefore, to note a fairly low LD₅₀ value in some of the murine strains. Histopathological examination has revealed acute renal tubular necrosis (fig.) as one of the causes of death. PGA has a low solubility in cold water but it dissolves in dilute solutions of alkali hydroxides and carbonates¹¹. Vitamin B₁₂ and folic acid appear to require binding to polypeptides as a precondition for storage. Levels above the serum and tissue-binding capacity tend to be excreted rather than retained¹⁴. The renal tubular necrosis observed by us might have been due to precipitation in the acidic urine within the tubules. This could result in renal shut-down and death after several hours or days. However, since the drug was given on a mg/kg basis, the large differences between various strains were surprising, especially because they were housed under identical experimental conditions and were given the same diet. Preterminal convulsions in only 2 strains and ataxia in the others suggest a specific susceptibility of certain strains possibly due to a difference in the metabolic conversion of the drug by the animal. It was interesting to note that C57BL/6 mice which are used for transplantation of Lewis lung carcinoma (LL) and B16 melanoma (B16) have a relatively low LD₅₀ value. LL responds well to methotrexate¹⁵. This suggests a possible biochemical uniqueness in the metabolic transformation of PGA by this specific strain.

The behavioral changes such as hyperkinesia and ataxia, convulsions and also coma suggested neural involvement. It is known that folic acid at a dose of 15 mg per day for 1–4 weeks to patients exacerbates epilepsy⁶ and 5-methyltetrahydrofolate has been reported to be neurotoxic^{16,17}. We did not detect any structural changes in the CNS of the mice treated with folic acid. It is possible that definite histological alterations may become manifest only after chronic repeated administration of folic acid. The acute changes in CNS function which were detected by us may have resulted from acute uremia resulting from renal tubular necrosis. No firm opinion regarding the CNS can be given on the basis of the present study.

In conclusion, it may be said that the administration of folic acid to different strains of mice by the i.p. route has shown a unique pattern of toxicity. The most common observation in the PGA-treated mice is renal tubular necrosis.

- 1 To whom correspondence and reprint requests should be sent (at the Chemotherapy Division)
- 2 Acknowledgment. The authors thank Ms N. Hasgekar for her technical assistance.
- 3 Wills, L., Clutterbuck, P.W., and Evans, P.D.F., *Biochem. J.* 31 (1937) 2136.
- 4 Mitchell, H.K., Snell, E.E., and Williams, R.J., *J. Am. chem. Soc.* 63 (1941) 2284.
- 5 Erbe, R.W., *New Engl. J. Med.* 293 (1975) 753.
- 6 Hillman, R.S., in: *The pharmacological basis of therapeutics*, 6th edn, p. 1331. Eds A.G. Gilman, L.S. Goodman and A. Gilman. Macmillan Publishing Co. Inc, New York 1980.
- 7 Parchure, M., Ambaye, R.Y., and Gokhale, S.V., *Chemotherapy*, in press (1984).
- 8 Cited from National Technical Information Service, US Dept. of Health and Human Services, NIOSH, Cincinnati, Ohio 1979.
- 9 Belies, R.P., *Toxic. appl. Pharmac.* 23 (1972) 537.
- 10 Windholz, M., Budavari, S., Stroumstos, L.Y., and Fertig, M.N., in: *The Merck Index*, 9th edn, p. 543. Merck and Co. Inc. Rahway, New Jersey 1976.
- 11 Wade, A., in: *Martindale, The extra pharmacopoeia incorporating Squire's companion*, 27th edn, p. 1683. The pharmaceutical press, London 1978.
- 12 Randelia, H.P., Hilgers, J., Hilkens, J., Krozen, V., Holmes, R., and Vandenberg, J., *Lab. anim.* 17 (1983) 280.
- 13 Miller, L.C., and Tainter, M.L., *Proc. Soc. exp. Biol. Med.* 57 (1944) 261.
- 14 Herbert, V., in: *Modern nutrition in health and disease*, 5th edn, p. 221. Eds R.S. Goodhart and M.E. Shills, Lea and Febiger, Philadelphia 1974.
- 15 Goldin, A., Venditti, J.M., Macdonald, J.S., Muggia, F.M., Henney, J.E., and DeVita, V.T. Jr, *Eur. J. Cancer* 17 (1981) 129.
- 16 Olney, J.W., Fuller, T.A., and Gubareff, T., *Nature* 292 (1981) 165.
- 17 Roberts, P.J., Foster, G.A., and Thomas, E.M., *Nature* 293 (1981) 654.

0014-4754/85/010072-02\$1.50 + 0.20/0

© Birkhäuser Verlag Basel, 1985

Circling behavior induced by phencyclidine in mice and its inhibition by naloxone

Y. Eshel and A.M. Korczyn*

Department of Physiology and Pharmacology, Sackler School of Medicine, Tel Aviv University, Ramat Aviv, 69978 Tel Aviv (Israel), 20 December 1983

Summary. Phencyclidine (PCP), when given to mice, induces general hyperactivity and rapid circling, similar to that caused by morphine. These effects are partially antagonized by naloxone.

Key words. Mice; circling behavior; phencyclidine; naloxone; hyperactivity.

Mice and rats manifest their activity by circling around the walls of a container in which they are placed. Animals have an innate preferred direction of circling, either clockwise or counter-clockwise. This tendency has been attributed to asymmetry between the two nigrostriatal systems¹.

Dopaminergic drugs increase the rate of circling and the degree of asymmetry². Morphine, although not a direct dopaminergic agent, also increases, in mice, the rate of circling in the preferred direction^{3,4}.

Phencyclidine has previously been reported to induce rotatory behavior in rats with unilateral nigrostriatal lesions^{5–7} as well as in intact rats⁸. This effect was attributed to interaction with

the dopaminergic nigrostriatal system^{5–8}. However, PCP shares some similarities with opiates⁹ and in the present study we examined the possibility that the rotatory behavior induced by PCP is also mediated through opiate mechanisms.

Materials and methods. Male ICR albino mice weighing 20–35 g were studied. Rotation was measured as previously described⁴. Morphine sulfate (Assia), 40 mg/kg, phencyclidine hydrochloride (prepared by A. Kalir), 5 mg/kg and naloxone (Du Pont), 10 mg/kg, were injected i.p. Each dose was given to eight mice. Before drug administration each animal was harnessed to the rotometer for 1 h to verify its basic circling rate and preferred direction. Control groups were injected with saline prior to na-

loxxone. The timing of naloxone injection was chosen so that its maximal effect will coincide with the peak effect of morphine or PCP.

Results. Basic circling rates were low and did not exceed 10 turns per hour. Naloxone did not affect the circling rate significantly, as was found previously¹⁰. Morphine, 40 mg/kg, markedly increased the preferred turns up to 215/h. The peak effect occurred 40 min after drug administration. Naloxone decreased the morphine score to 45 preferred turns per hour (see fig. 1 and the table for further details).

Performance of mice injected with morphine (40 mg/kg), PCP (5 mg/kg) alone or in combination with naloxone (10 mg/kg). Each group contained 8 mice. Volumes indicate mean \pm SEM

	Morphine	Morphine and naloxone	PCP	PCP and naloxone
Total turns/h	230 \pm 21	52 \pm 7*	170 \pm 20	80 \pm 7*
Preferred turns/h	215 \pm 23	45 \pm 8* (21%)	160 \pm 19	70 \pm 7* (44%)**
Total nonturn movements/h	1040 \pm 156	74 \pm 17* (7%)	960 \pm 75	460 \pm 52* (48%)**
Preferred nonturn movements/h	720 \pm 75	30 \pm 3* (4%)	510 \pm 47	260 \pm 26* (51%)**

* Statistically significant (Student's paired t-test) from the nonnaloxone score ($p < 0.01$). ** Statistically significant (Student's t-test) from the naloxone effect after morphine ($p < 0.001$).




Figure 1. Turning behavior measured as preferred turns per hour of 8 mice injected with morphine, 40 mg/kg, and morphine and naloxone, 10 mg/kg, bars indicate SEM.




Figure 2. Turning behavior measured as preferred turns per hour of 8 mice injected with PCP, 5 mg/kg and PCP and naloxone, 10 mg/kg, bars indicate SEM.

PCP, 5 mg/kg, increased the preferred turns up to 160/h (peak effect, 20 min following drug administration). The effect of PCP lasted for 1 h. Naloxone antagonized this PCP effect, reducing it to 70 turns per hour (fig. 2 and the table). General motor activity, measured as nonturn movements per hour, was also antagonized by naloxone. However, the effect of naloxone was much lower against PCP-induced circling (and hyperactivity) than against the respective morphine effects (table). **Discussion.** In the present work we have demonstrated that mice respond to PCP with hyperactivity and rotatory behavior. The circling is similar to that described in rats by Glick et al.⁸. Murray and Horita¹¹ found that PCP administered to rats induced turning behavior, in which the animals pivot around their hind limbs. These workers suggested that this type of turning is an expression of stereotyped behavior¹¹. Phenomenologically it is different from the running observed by us in mice, or by Glick et al. in rats, although what we observed can probably be called stereotyped turning.

Previous workers³⁻⁸ concluded that PCP interacts with dopaminergic mechanisms to produce circling in rats. This conclusion was based on the similarity between the effects of PCP and amphetamine and the antagonism of PCP-induced circling by neuroleptic drugs^{7,11}. The use of neuroleptics, however, is not specific since any drug interfering with motility will antagonize both hyperactivity and circling.

The present results demonstrate that, as suggested by Glick et al.⁸, circling induced by PCP is a complex action. Part of this effect is naloxone sensitive, i.e. mediated through opiate receptors. This could imply a direct interaction between PCP and opiate receptors¹² or release of endogenous endoporphins by PCP, as suggested by us for somatostatin¹³.

In contrast to opiate-induced rotation, the phenomenon caused by PCP was only incompletely blocked by naloxone (in spite of the high dose of the antagonist used by us). A similar phenomenon exists for other systems, e.g. PCP-induced antagonism of guinea-pig ileum contraction, which is only partially naloxone-sensitive¹⁴. The reason is unclear, and may possibly indicate that the PCP effect occurs through different mechanisms¹⁴.

* Acknowledgment. We are grateful to Professor A. Kalir for the donation of PCP. Correspondence and reprint requests should be addressed to A.M. Korczyn.

- Glick, S.D., Simmerberg, G., and Greenstein, S., *Brain Res.* 105 (1976) 363.
- Keren, O., and Korczyn, A.D., *Experientia* 34 (1978) 616.
- Glick, S.D., Cox, R.D., Jerussi, T.P., and Greenstein, S., *J. Pharm. Pharmac.* 29 (1977) 51.
- Korczyn, A.D., and Eshel, Y., *Neuroscience* 4 (1979) 1085.
- Kanner, M.I., Finnegan, K.T., and Meltzer, H.Y., *Psychopharmac. Commun.* 114 (1975) 393.
- Finnegan, K.T., Kanner, M.I., and Meltzer, H.Y., *Pharmac. biochem. Behav.* 5 (1976) 651.
- Meltzer, H.Y., Sturgeon, R.D., Simonovic, M., and Fessler, R.G., *Psychopharmac. Bull.* 16 (1980) 62.
- Glick, S.D., Meibach, R.C., Cox, R.D., and Maayani, S., *Brain Res.* 196 (1980) 99.
- Sturgeon, R.D., Fessler, R.G., London, S.F., and Meltzer, H.Y., *Eur. J. Pharmac.* 76 (1981) 37.
- Rabinowitz, R., Shlesinger, N., and Korczyn, A.D., *Pharmac. Res. Commun.* 15 (1983) 963.
- Murray, T.F., and Horita, A., *Life Sci.* 24 (1979) 2217.
- Itzhak, Y., Kalir, A., Weissman, B., and Cohen, S., *Eur. J. Pharmac.* 72 (1981) 305.
- Eshel, Y., Sarne, Y., and Korczyn, A.D., *Life Sci.* 32 (1981) 1053.
- Itzhak, Y., Kalir, A., and Sarne, Y., *Eur. J. Pharmac.* 73 (1981) 229.